Privately-owned Prosensa Therapeutics BV of the Netherlands has raised €23 million to support its pipeline which includes a Phase 3 RNA-modulating therapeutic for Duchenne muscular dystrophy. New Enterprise Associates Inc led the financing.
A new life science facility is set to open in Scotland providing small companies with shared resources for their drug discovery and development. Called BioCity Scotland Ltd, the facility is being housed at a former Merck Sharp & Dohme (MSD) research site.
Immatics Biotechnologies GmbH has reported that a Phase 2 study of its experimental vaccine for colorectal cancer, IMA910, was able to stimulate immune responses from a majority of patients and that this was associated with a better clinical outcome.
T
Sanofi SA has received FDA approval of its plant in Framingham, Massachusetts with the result that it can start restoring supplies of its treatment for Fabry disease. The FDA approval follows earlier approval by the European Medicines Agency.
The US Food and Drug Administration has approved the first diagnostic that will enable healthcare professionals to determine whether a patient taking the multiple sclerosis drug, Tysabri (natalizumab), faces a risk of the brain infection, PML.
Novartis’s new treatment for Cushing’s disease, a rare hormonal disorder, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use.
The European Medicines Agency has announced the start of a safety review of the Novartis treatment for multiple sclerosis, Gilenya (fingolimod), less than a year after the drug was authorised for marketing in the European Union.
4SC AG has reported new data showing that its lead oncology compound, resminostat, an HDAC inhibitor, met its primary endpoint in a Phase 2 study of patients with advanced liver cancer. The results were reported on 19 January.
The US Food and Drug Administration has turned down a new treatment for type 2 diabetes, dapagliflozin, the drug’s co-developers, AstraZeneca Plc and Bristol-Myers Squibb Company announced. The drug inhibits sodium-glucose transport proteins known as SGLT2.
In the wake of its acquisition of Nycomed A/S, and in order to increase productivity, Takeda Pharmaceutical Company Ltd is to embark on a five-year restructuring that will result in job losses of 2,800 globally, of which 2,100 will be in Europe.